
Releases
ADMA Biologics Faces Class Action Over Alleged Securities Violations
Investors who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, are facing an August 10 deadline to join a class action lawsuit. The legal action centers on allegations that the company deceived the market by inflating sales figures and failing to disclose related party transactions.



.jpg)


















